Botulinum toxin type A for the treatment of lower urinary tract disorders
T Yokoyama, MB Chancellor, K Oguma… - … journal of urology, 2012 - Wiley Online Library
Many papers report the clinical success of botulinum toxin A as a method of management of
various bladder dysfunctions. The rationale was that botulinum toxin A was able to block the …
various bladder dysfunctions. The rationale was that botulinum toxin A was able to block the …
Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis
ASOM Goessaert, KCMM Everaert - Expert Review of …, 2012 - Taylor & Francis
Evidence for the efficacy and safety of intravesical onabotulinum toxin A (onabotA) injections
has led to it being licensed in many countries in patients with urinary incontinence due to …
has led to it being licensed in many countries in patients with urinary incontinence due to …
Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB
L Brubaker, A Gousse, P Sand, C Thompson… - International …, 2012 - Springer
Introduction and hypothesis Clinically meaningful overactive bladder syndrome (OAB)
symptom relief is associated with patient satisfaction. This study evaluated the effects of …
symptom relief is associated with patient satisfaction. This study evaluated the effects of …
Standard pharmacological treatment and new therapies for overactive bladder
G Del Popolo, M Mencarini, V Li Marzi - Urologia Journal, 2012 - journals.sagepub.com
The prevalence of overactive bladder (OAB) in adult males varies from 10.2% to 17.4%, and
in females from 7.7 to 31.3. 16.5% of the adult population presents symptoms consistent with …
in females from 7.7 to 31.3. 16.5% of the adult population presents symptoms consistent with …
Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type A
C Sager, C Burek, V Durán, JP Corbetta… - International …, 2012 - Wiley Online Library
When the neurogenic bladder is refractory to anticholinergics, botulinum toxin type A is used
as an alternative. The neurotoxin type A reduces bladder pressure and increases its …
as an alternative. The neurotoxin type A reduces bladder pressure and increases its …
Botulinum toxin versus sacral neuromodulation for idiopathic detrusor overactivity
W Leicht, C Hampel, J Thüroff - Der Urologe, 2012 - Springer
Die idiopathische Detrusorüberaktivität (motorische Urge) hat einen negativen Einfluss auf
das Leben der betroffenen Patienten. Konservative Therapien führen nicht immer zu einer …
das Leben der betroffenen Patienten. Konservative Therapien führen nicht immer zu einer …
Difficult urination does not affect the successful outcome after 100U onabotulinumtoxinA intravesical injection in patients with idiopathic detrusor overactivity
YC CHEN, HC KUO - LUTS: Lower Urinary Tract Symptoms, 2012 - Wiley Online Library
Objectives: Intravesical injection of onabotulinumtoxinA (ie Botox) provides effective
treatment for overactive bladder. However, treatment‐related adverse events (AEs) remain …
treatment for overactive bladder. However, treatment‐related adverse events (AEs) remain …
[HTML][HTML] Do baseline urodynamic parameters affect the treatment outcome after intravesical 100 U onabotulinumtoxinA injection in patients with idiopathic detrusor …
QS Ke, YC Chen, HC Kuo - Tzu Chi Medical Journal, 2012 - Elsevier
OBJECTIVES: Intravesical injection of onabotulinumtoxinA (BoNT-A) provides effective
treatment for idiopathic detrusor overactivity (IDO). However, not all patients have successful …
treatment for idiopathic detrusor overactivity (IDO). However, not all patients have successful …
[PDF][PDF] Departamento de Uroneurologia
O Projeto Recomendações SBU 2012 foi elaborado pelos Departamentos da Sociedade
Brasileira de Urologia e seguiu o padrão do Projeto Diretrizes, uma iniciativa conjunta da …
Brasileira de Urologia e seguiu o padrão do Projeto Diretrizes, uma iniciativa conjunta da …
Léčba neurogenního hyperaktivního detruzoru aplikací botulinumtoxinum A
V Šámal - 2012 - dspace.cuni.cz
Léčba neurogenního hyperaktivního detruzoru aplikací botulinumtoxinu A Úvod: Léčba
neurogenní hyperaktivity detruzoru (NDO) představuje stále závažný zdravotní, sociální a …
neurogenní hyperaktivity detruzoru (NDO) představuje stále závažný zdravotní, sociální a …